SynAct Pharma Investor Relations Material
Latest events
CMD 2025
SynAct Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SynAct Pharma
Access all reports
SynAct Pharma AB, develops medicines for acute deterioration in inflammatory diseases. The company's lead product, Synacto®, is a mix of three anti-inflammatory protease inhibitors for the treatment of patients who have recently had a heart attack, have re-opened their old heart wounds due to surgery, or are going to undergo procedures in which blood clotting is needed. SynAct Pharma AB is based in Lund, Sweden.
Key slides for SynAct Pharma
CMD 2024
SynAct Pharma
CMD 2024
SynAct Pharma
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SYNACT
Country
🇸🇪 Sweden